t is conceptually similar to antibodies. Aptamers combine the
optimal characteristics of small molecules and antibodies, including high
specificity and affinity, chemical stability, and the ability to target
protein-protein interactions. In contrast to monoclonal antibodies,
aptamers are chemically synthesized, rather than biologically expressed,
and may offer significant manufacturing advantages.
SomaLogic, Inc. is a privately-held biomarker discovery and clinical
proteomics company based in Boulder, Colorado. The company's mission is to
use its proprietary aptamer technology to develop aptamers with remarkable
affinity and specificity for their molecular targets, and to develop
enhanced protein analysis tools and reagents for the life sciences
community. SomaLogic is developing and commercializing clinical diagnostic
products that will improve the delivery of healthcare by offering timely
and accurate diagnostic information to physicians and their patients.
SomaLogic's aptamer expertise is complemented by a robust patent estate
comprised of over 220 issued and 230 pending patents covering the
identification, composition, and use of diagnostic aptamers. In addition to
the company's core aptamer generation technology, SomaLogic possesses deep
expertise in the use and development of aptamer arrays for biomarker
discovery, life sciences research, and clinical diagnostics.
Further information about SomaLogic can be found at
Direct contact can be arranged through email@example.com or through
Anne Wong at firstname.lastname@example.org.
About Otsuka Pharmaceutical Co., Ltd.
Founded in 1964, Otsuka Pharmaceutical Co., Ltd. is a global healthcare
company with the corporate philosophy: 'Otsuka -- people creating new
products for better health worldwide.' Otsuka rPage: 1 2 3 Related biology technology :1
. New Drug Application for Tolvaptan, Otsukas Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia, Accepted by the U.S. Food and Drug Administration2
. Otsuka Pharmaceutical and PDL BioPharma Close Sale of IV Busulfex3
. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.4
. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems5
. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training6
. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers7
. Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.18
. UniCare Unveils Community Resource Center in Topeka to Serve Medicaid Enrollees9
. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products10
. Neogen Acquires Kane Enterprises11
. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma